Last reviewed · How we verify
NCT04447963
Evaluation of Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Wrinkles
NA trial testing Non-invasive treatment of facial wrinkles in Wrinkle in 51 participants. Completed in 28 June 2021.
31 March 2021
Quick facts
| Lead sponsor | BTL Industries Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 51 |
| Start date | 15 June 2020 |
| Primary completion | 31 March 2021 |
| Estimated completion | 28 June 2021 |
| Sites | 1 location across Bulgaria |
Drugs / interventions tested
- Non-invasive treatment of facial wrinkles
Conditions studied
- Wrinkle — all drugs for Wrinkle →
Sponsor
BTL Industries Ltd. — full company profile →
Who can join
Adults 21 to 70, any sex, with Wrinkle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the clinical safety and the performance of the BTL-785F system equipped with BTL-785-2 applicator for non-invasive treatment of facial wrinkles.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04447963
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Wrinkle
Currently open trials in the same condition.
- NCT06868615 — AVAVA MIRIA General Use · NA · recruiting
- NCT06571721 — The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles · NA · recruiting
- NCT06385171 — Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation · recruiting
- NCT06557434 — AV-23-001 AVAVA MIRIA Pilot Study · NA · active not recruiting
- NCT06202274 — Clinical Study to Evaluate the Safety and Efficacy of Candela Technology · NA · active not recruiting
Other BTL Industries Ltd. trials
Trials by the same sponsor.
- NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
- NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting
- NCT07179224 — EEG Changes After rTMS Stimulation · NA · completed
- NCT07024550 — Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway · NA · active not recruiting
- NCT07027657 — EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04447963 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BTL Industries Ltd.
- Last refreshed: 10 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04447963.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing